Watermark
  Back to Search Results

BGB-A317-306

Completed

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-306

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT03783442

EudraCT or EUCT Number Info icon SVG graphic used for tooltips or additional information.

2018

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20181013

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan Plain Language Summary

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan Plain Language Summary